Transporters and drug disposition

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 1, 2000, Pages 94-101

  Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absorption; Distribution; Drug drug interaction; Hepatic transporters; P glycoprotein

Indexed keywords

BILE ACID; GLYCOPROTEIN P;

ARTICLE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; NONHUMAN;

EID: 0033974854     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Guengerich FP: Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett (1994) 70:133-138.
2. Hagenbuch B, Jacquemin E, Meier PJ: Na'-dependent and Na'-independent bile acid uptake systems in the liver. Cell PhysiolBiochem(W94) 4:19-205.
3. Hagenbuch B, Stieger B, Foguet M, Lübbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte NaYbile acid cotransport system. Proc Natl AcadSci USA (1991) 88:10629-10633.
4. Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver NaVbile acid cotransporter. J Clin Invest (1994) 93:1326-1331.
5. Hagenbuch B, Scharschmidt BF, Meier PJ: Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevls oocytes. Biochem J (1996) 316:901-904.
6. Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, Wilkinson GR: Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptlde) activity. J PharmacolExp 77)er(1999) 291:1204-1209.
7. Demonstrates that many drugs can inhibit the bile acid uptake transporter NTCP, without being transport substrates.
8. Ishi K, Wolkoff AW: Inhibition of rat hepatocyte organic anion transport by bile acids. Am J Physiol (1994) 267:G458-G464.
9. Jacquemin E, Hagenbuch B, Steiger B, Wolkoff AW, Meier PJ: Expression cloning of a rat liver Na'-independent organic anion transporter. Proc Natl Acad Sci USA (1994) 91:133-137.
10. This is the first reported cloning of an Oatp transporter.
11. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol (1996) 270:F326-F331.
12. Bossuyt X, Müller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther (1996)276:891-896.
13. Reveals the diversity of drug substrates for the Oatpl transporter.
14. Eckhardt U, Horz JA, Petzinger E, Stüber W, Reers M, Dickneite G, Daniel H, Wagener M, Hagenbuch B, Stieger B, Meier PJ: The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic aniontransporting polypeptide. Hepatology (1996) 24:380-384.
15. Noé B, Hagenbuch B, Stieger B, Meier PJ: Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA (1997) 94:10346-10350.
16. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ: Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem (1999) 47:1255-1264.
17. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999)27:866-871.
18. Detailed description provided on setting up and utilizing the recombinant vaccinia system for expressing drug uptake transporters.
19. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, Yawo H: Molecular characterization and tissue distribution of a new organic anion transporter subtype (Oatp3) that transports thyroid hormones and taurocholate and comparison with Oatp2. J Biol Chem (1998) 273:22395-22401.
20. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H: Identification of a novel gene family encoding human liverspecific organic anion transporter LST-1. J Biol Chem (1999)274:17159-17163.
21. Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, Matsuno S, Yawo H, Abe T: Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology (1999) 117:770-775.
22. Saito H, Masuda S, Inui K: Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem (1996) 271:20719-20725.
23. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Sc/ence(1995) 268:866-869.
24. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT). J Clin Invest (1996) 98:1142-1149.
25. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 372:549-552.
26. Fei Y-J, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA: Expression cloning of a mammalian proton-coupled oligopeptide transporter. /Vafure(1994) 368:563-566.
27. Liang R, Fei Y-J, Prasad PD, Ramamoorthy S, Han H, YangFeng TL, Hediger MA, Ganapathy V, Leibach FH: Human intestinal H'/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem (1995)270:6456-6463.
28. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Mod (1991) 42:277-286.
29. Ling V: Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol (1997) 40(Suppl):S3-S8.
30. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJ, Borst P: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 75:451-462.
31. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedier JL, Melarned MR, Bertino JR: Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Nail Acad Sci USA (1989) 86:695-698.
32. Levêque D, Jehl F: P-glycoprotein and pharmacokinetics. Anticancer Res (1995) 15:331-336.
33. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and Pglycoprotein. Pharm Res (1999) 16:408-414.
34. Shows that substrate overlap between CYP3A and P-gp is incomplete.
35. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoproteln-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation (1999) 99:552-557.
36. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease Inhibitors. J Clin Invest (1998) 101:289-294.
37. Schuetz EG, Yasuda K, Arimori K, Schuetz JD: Human MDR1 and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys (1998)350:340-347.
38. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol ÇA, van der Valk MA, RobanusMaandag EC, Riele HPJ, Berns AJ, Borst P: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 77:491 -502.
39. This is a classic paper showing the importance of P-gp to drug disposition.
40. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin /nvesf (1995) 96:1698-1705.
41. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin /nvesr(1996) 97:2517-2524.
42. Wacher VJ, Wu C-Y, Benêt LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Caranog (1995) 13:129-134,
43. Reviews evidence that supports the notion of a broad substrate overlap between CYP3A and P-gp.
44. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol (1996) 49:311-318.
45. First experimental evidence showing coordinate regulation and function of P-gp and CYP3A.
46. Wandel C, Kim RB, Kajiji S, Guengerich P, Guengerich FP, Wilkinson GR, Wood AJ: P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res (1999) 59:3944-3948.
47. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 271:1126-1128.
48. Paulusma CG, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP: A mutation in the human canalicular multispecific organic anion transporter gène causes thé Dubin-Jonnson syndrome. Hepatology (1997) 25:1539-1542.
49. Oude Elferink RP, Jansen PL: The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. Pharmacol T/7er(1994) 64:77-97.
50. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, Sugiyama Y: Hepatic expression of multidrug resistanceassociated protein-like proteins maintained in Eisal hyperbilirubinemic rats. Mol Pharmacol (1998) 53:1068-1075.
51. Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB: Human MRP3 transporter: Identification of the S'-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta (1999) 1415:369-374.
52. Konig J, Rost D, Cui Y, Keppler D: Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology (1999) 29:1156-1163.
53. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ: The sister of Pglycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem (1998) 273:1004610050.
54. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Amell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, MieliVergani G, Freimer NB, Gardiner RM, Thompson RJ: A gene encoding a liver-specific ABC transporter Is mutated in progressive familial intrahepatic cholestasis. Nature Genet (1998)20:233-238.
55. Reichel C, Gao B, Van Montfoort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, Kamisako T, Meier PJ: Localization and function of the organic aniontransporting polypeptide Oatp2 in rat liver. Gastroenterology (1999) 117:688-695.
56. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y: Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. J PharmacolExp T/7er(1999) 290:1107-1115.